Shanghai Medicilon, Inc.

Shanghai Medicilon, Inc. has seen a notable rise in stock performance, gaining 9.26% on July 21, 2026, and reaching an intraday high of CNY 80.50. Over the past month, the company has grown significantly, contrasting with the broader market trends, while facing challenges such as negative return on equity.

Shanghai Medicilon, Inc. experienced notable stock volatility on July 17, 2026, with a significant decline amid a less severe drop in the broader market. Despite a recent recovery and positive monthly performance, the company faces long-term growth challenges, reflected in its declining operating profit and high-risk trading position.

Shanghai Medicilon, Inc. has seen a notable rise in stock performance, achieving significant gains over the past week and month. In contrast, the China Shanghai Composite index has declined. Despite short-term successes, the company faces long-term growth challenges, with fluctuating net sales and operating profit.

Shanghai Medicilon, Inc. has seen notable stock activity, achieving significant short-term gains while contrasting with the broader market. Despite impressive recent performance, the company faces challenges in long-term growth, with net sales increasing modestly over five years and declines in stock performance over longer periods.

Shanghai Medicilon, Inc. has shown strong stock performance recently, gaining 6.42% on June 18, 2026, despite a decline in the broader market. Over the past year, the company has achieved a notable 68.61% increase, although it has faced challenges with a five-year performance decline of 89.5%.

Shanghai Medicilon, Inc. faced a notable decline today, with its stock dropping significantly. Over the past week and month, the company has experienced pronounced downturns, despite a strong annual performance. Long-term prospects appear challenging, marked by a substantial drop over five years and concerning financial metrics.

Shanghai Medicilon, Inc. has seen a notable increase in its stock today, contrasting with the broader market's modest gains. Over the past week, the company has shown strong performance, although it has faced longer-term challenges, including a significant decline over the past month and three years. Despite this, it has achieved impressive annual growth.

Shanghai Medicilon, Inc. saw a significant intraday increase on March 24, 2026, contrasting with the broader market's performance. Despite recent declines over the week and month, the company has achieved substantial annual growth. Its market capitalization is CNY 7,306 million, with key financial metrics indicating challenges ahead.

Shanghai Medicilon, Inc. faced a notable decline today, with its stock dropping significantly. Over the past week and month, the company has experienced substantial downturns, contrasting with its previous year’s performance. Long-term metrics reveal ongoing challenges, including significant decreases over three and five years, raising concerns about its financial health.

Shanghai Medicilon, Inc. faced a notable decline in stock performance, reflecting ongoing challenges with significant drops over the past week and month. Despite a year-over-year increase, the company has struggled year-to-date and over the past three to five years, indicating potential financial instability and a lack of dividend yield.

Shanghai Medicilon, Inc. faced a notable decline today, with a 7.27% drop in stock price. Over the past week, the company has decreased by 16.09%, while its long-term performance shows significant declines over three and five years. Despite recent challenges, it has achieved a 71.4% increase over the past year.

Shanghai Medicilon, Inc. saw a notable decline in its stock price, contrasting with the broader market's performance. While the company has experienced impressive annual growth, its long-term outlook is challenging, marked by significant declines over three and five years. The company's financial metrics indicate a high dividend yield of 0.00% and negative return on equity.

Shanghai Medicilon, Inc. saw a notable decline in its stock today, contrasting with the broader market's performance. While the company has experienced positive year-to-date and annual growth, it faces challenges in long-term profitability, with net sales increasing but operating profit declining significantly over the past five years.

Shanghai Medicilon, Inc. has seen a significant stock increase today, contrasting with a decline in the broader market. Over the past year, the stock has risen substantially, outperforming the China Shanghai Composite. However, the company faces long-term growth challenges, including declining operating profit and a high dividend yield of 0%.